Page 1

May 6 , 2021 XOMA XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events XOMA's portfolio of potential milestone and royalty assets now has greater than 70 drug candidates . Company ended the first quarter of 2021 with $ 67.8 million in cash . The April 2021 $ 40 million Series B Perpetual Preferred Stock offering paying 8.375 % dividend increased XOMA's cash and restricted cash to over $ 100 million . Board of Directors approved first quarterly dividend payment for XOMAP . On May 3 , XOMA announced Janssen had dosed the first patient in a Phase 3 clinical study , resulting in a $ 0.5 million milestone . EMERYVILLE , Calif . , May 06 , 2021 ( GLOBE NEWSWIRE ) -- XOMA Corporation ( Nasdaq : XOMA ) reported its first quarter 2021 financial results and provided a recent operations update . " Our team continues to identify exciting assets to add to our milestone and royalty portfolio . Their efforts resulted in our acquisition of two economic licenses from Viracta during the first quarter . We were delighted to add Day One Biopharmaceuticals ' DAY101 ( pan - RAF kinase inhibitor ) and Denovo Biopharma's vosaroxin ( topoisomerase II inhibitor ) to our growing list of partner - funded assets , " stated Jim Neal , Chief Executive Officer of XOMA . " I am proud that our team continues to be productive in this COVID - impacted environment . " In addition , since the close of the first quarter , we added three clinical - stage assets to our portfolio , AFM13 , AFM24 , and an undisclosed asset , each of which resulted from a research and discovery license agreement we established with Affimed fifteen years ago . These are three interesting oncology assets as they are designed to activate the body's innate immune system to kill cancer cells . We believe the initial data from the AFM13 Phase 1 study in patients with relapsed / refractory CD30 + lymphomas , recently presented at the AACR Virtual Annual Meeting , are encouraging . This week , we received notification from Janssen that the first patient has been dosed in the inaugural cetrelimab Phase 3 clinical study , making it the second molecule in our portfolio to advance to the final stage of clinical development . " To continue to support our strategy to expand our potential milestone and royalty portfolio via acquisition transactions , in April we completed a $ 40 million offering of Series B Perpetual Preferred Stock , which pays an 8.375 % dividend , bringing our cash and restricted cash to over $ 100 million . And finally , we paid our first dividend on the Series A Perpetual Preferred Stock . Today , we have one of the strongest financial positions in our recent history , particularly when coupled with our very lean expense structure . " Financial Results